Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04479358 · ClinicalTrials.gov registry record · Phase 2
Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT04479358 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 85 participants.
The verdict
NCT04479358, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
Tocilizumab is an effective treatment for severe coronavirus disease 2019 (Covid-19) pneumonia and related inflammation. Given limited global supplies, clarification of the optimal tocilizumab dose is critical. We conducted an open-label, randomized, controlled trial evaluating two different dose levels of tocilizumab in Covid-19 (40mg and 120mg). Randomization was stratified on remdesivir and corticosteroid at enrollment. The primary outcome was the time to recovery. The key secondary outcome was 28-day mortality.
Interventions
- OTHER Standard of Care
- DRUG Tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2020-09-10 |
| Est. Completion | 2025-02-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04479358
The ClinicalTrials.gov registry entry for NCT04479358 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT04479358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04479358 about?
NCT04479358 is a clinical study titled "Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19". Tocilizumab is an effective treatment for severe coronavirus disease 2019 (Covid-19) pneumonia and related inflammation. Given limited global supplies, clarification of the optimal tocilizumab dose is critical. We conducted an open-label, randomized, controlled trial evaluating two different dose le...
What is the current status of trial NCT04479358?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2020-09-10. Estimated completion is 2025-02-10.
What interventions are being tested in trial NCT04479358?
The interventions under investigation include: Standard of Care (OTHER), Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT04479358?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.